Lhe Walloon region and private investors are funding the new spin-off of the University of Liège and WelBio with 4.5 million euros. Called THERAtRAME, it is a new drug discovery platform.
THERAtRAME is a biotech specialized in the research of therapies once morest cancer and which relies on the vulnerabilities of the disease, hitherto ignored. The method used is the fruit of research by the GIGA institute of the University of Liège, the interdisciplinary research center in biomedical sciences and WelBio.
The platform aims to create new therapies, targeting the weaknesses of cancer, ignored for a long time. Using artificial intelligence and mathematical models, researchers hope to find new treatments. THERAtRAME will have access to bio-banks of patient samples.
Until today, the spin-off has received a lot of financial support from universities, public funds, technology companies as well as private investors.
